What is the recommended management of antiphospholipid syndrome, including anticoagulation strategies, pregnancy considerations, primary prophylaxis, and treatment of catastrophic antiphospholipid syndrome?

Management of Antiphospholipid Syndrome

For thrombotic APS, use vitamin K antagonists (VKAs) targeting INR 2-3 for venous events and consider INR 2-3 or 3-4 for arterial events; for obstetric APS, combine low-dose aspirin with prophylactic LMWH throughout pregnancy; and for catastrophic APS, immediately initiate triple therapy with anticoagulation, high-dose corticosteroids, and plasma exchange. 1

Risk Stratification and Primary Prophylaxis

High-risk antiphospholipid antibody (aPL) profile includes triple positivity (lupus anticoagulant + anticardiolipin + anti-β2-glycoprotein I antibodies), which carries the greatest thrombotic risk 1.

For asymptomatic aPL carriers with high-risk profiles:

• Prescribe low-dose aspirin (75-100 mg daily) as primary prophylaxis 1
• This recommendation strengthens when cardiovascular risk factors coexist or systemic lupus erythematosus is present 2
• Address modifiable risk factors: smoking cessation, hypertension control, lipid management, and obesity reduction 1

Secondary Thrombosis Prophylaxis (Post-Thrombotic APS)

Venous Thrombosis

Use VKAs with target INR 2-3 indefinitely after first unprovoked venous thromboembolism 1. This represents the gold standard based on guideline consensus.

Critical caveat regarding DOACs: Rivaroxaban should NOT be used in triple-positive APS patients due to increased thrombotic risk demonstrated in trials 1. While some guidelines suggest DOACs may be considered in low-risk venous APS (negative lupus anticoagulant), the evidence remains insufficient for broad recommendation 3, 4.

Arterial Thrombosis

Start VKA with target INR 2-3, or consider INR 3-4 based on individual bleeding versus thrombosis risk assessment 1. Arterial events carry higher recurrence rates, justifying consideration of:

• VKA alone with INR 2-3
• VKA with INR 3-4 in high-risk patients
• Addition of low-dose aspirin to VKA therapy 4

The choice between these strategies depends on bleeding risk, prior event severity, and aPL profile intensity.

Refractory Thrombosis (Recurrence Despite Adequate Anticoagulation)

When thrombosis recurs on therapeutic anticoagulation, escalate treatment by:

1. Adding low-dose aspirin to existing VKA therapy
2. Increasing INR target to 3-4
3. Switching to therapeutic-dose LMWH if VKA fails 1

Consider adding hydroxychloroquine, which has emerging evidence for thrombosis risk reduction 2.

Obstetric APS Management

Standard Obstetric APS

For women with definite obstetric APS (≥3 pregnancy losses), prescribe combination therapy: low-dose aspirin (75-100 mg daily) plus prophylactic-dose LMWH throughout pregnancy and 6 weeks postpartum 5, 6, 1.

Key implementation details:

• Start aspirin preconceptionally or by gestational week 16 at latest 5
• LMWH is preferred over unfractionated heparin for practical reasons despite RCT evidence existing only for unfractionated heparin 5
• Continue anticoagulation minimum 6 weeks postpartum (total treatment duration ≥3 months) 6
• This regimen achieves live birth rates of approximately 70% 2

Refractory Obstetric APS

When pregnancy complications recur despite standard therapy:

1. Increase heparin to therapeutic dosing
2. Add hydroxychloroquine (emerging evidence supports benefit)
3. Add low-dose prednisolone in first trimester (5-10 mg daily) 1

Important Pregnancy Monitoring

• Supplement with calcium, vitamin D, and folic acid, particularly in patients receiving glucocorticoids or heparin 5
• Monitor for placental insufficiency and fetal growth restriction to optimize delivery timing 5
• Perform fetal echocardiography if anti-Ro/SSA or anti-La/SSB antibodies are positive 5

Women with Prior Thrombotic APS Who Become Pregnant

Switch from VKA to LMWH immediately upon pregnancy confirmation 6:

• VKAs are teratogenic in first trimester (Grade 1A evidence)
• VKAs increase bleeding risk when delivery is imminent (Grade 1A evidence)
• Perform frequent pregnancy tests in women attempting conception on VKAs to enable rapid switching 6

Non-Pregnant Women with Obstetric APS Only

Prescribe low-dose aspirin if high-risk aPL profile is present to prevent future thrombotic events 1.

Catastrophic Antiphospholipid Syndrome (CAPS)

CAPS requires immediate recognition and aggressive triple therapy: full-dose anticoagulation + high-dose corticosteroids + plasma exchange, with consideration of intravenous immunoglobulin 4, 7, 8.

Recognition

CAPS presents as rapid-onset multiorgan failure from diffuse microvascular thrombosis, affecting <1% of APS patients but carrying 30-50% mortality 4, 7. The clinical picture often mimics sepsis initially, creating diagnostic confusion 9.

Treatment Algorithm

1. Anticoagulation: Initiate therapeutic-dose heparin immediately (LMWH or unfractionated heparin)
2. High-dose corticosteroids: Methylprednisolone 1000 mg IV daily for 3 days, then taper
3. Plasma exchange: Begin urgently, typically daily sessions
4. IVIG: Add 0.4 g/kg daily for 5 days if inadequate response 4, 7

Critical timing: Early initiation of this combined approach significantly reduces mortality 4. Delayed treatment is associated with fatal outcomes, as illustrated by case reports where anticoagulation and plasma exchange were withheld 9.

Triggering Factors to Address

• Infections (most common trigger—treat aggressively)
• Surgical procedures
• Anticoagulation withdrawal
• Medications 7

Special Populations and Pitfalls

Women with Inherited Thrombophilia and Pregnancy Complications (Without aPL)

Do NOT use antithrombotic prophylaxis 6. This represents a common pitfall—inherited thrombophilia alone without aPL does not warrant treatment.

Women with Recurrent Miscarriage Without aPL or Thrombophilia

Do NOT prescribe antithrombotic prophylaxis (Grade 1B evidence) 6. Aspirin and heparin provide no benefit in this population.

"Seronegative" APS or Patients Not Meeting Classification Criteria

Exercise clinical judgment when patients have suggestive clinical features but don't meet formal criteria (e.g., only low-titer antibodies, only IgM isotype, or isolated early recurrent miscarriage). Balance potential treatment benefits against risks on an individual basis, recognizing that classification criteria were designed for research, not to exclude patients from treatment 10, 11.

Systemic Lupus Erythematosus with aPL (No Prior APS Events)

Prescribe low-dose aspirin if high-risk aPL profile is present 1. The coexistence of SLE increases baseline thrombotic risk.

Monitoring and Long-term Management

• Lifelong anticoagulation is required for thrombotic APS as aPL typically persist 4
• Patient education regarding medication adherence is critical—anticoagulation cessation can trigger CAPS 1
• Regular cardiovascular risk assessment and aggressive risk factor modification 1
• Avoid estrogen-containing contraceptives in women with thrombotic APS; consider progestin-only methods 5